Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in Weston, FL, dedicated to developing novel, well-tolerated oral treatments for cancer and other serious illnesses. Led by experienced drug developers and pharmaceutical executives, Cantex focuses on the development of azeliragon, a safe and promising antagonist of RAGE, the receptor for advanced glycation endproducts, targeting various cancers including glioblastoma, metastatic brain tumors, pancreatic cancer, and breast cancer, as well as the prevention of acute kidney injury in seriously ill patients.
With a strong emphasis on research and development, Cantex Pharmaceuticals is actively engaged in multiple clinical trials, collaborating with renowned medical institutions such as Michigan Medicine, Allegheny Health Network, and Lenox Hill Hospital's Department of Neurological Surgery. Committed to improving patient outcomes, Cantex aims to provide effective and accessible treatments for those facing challenging medical conditions.
Generated from the website